Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

9 Jan 2012 07:00

RNS Number : 1755V
Persimmon PLC
09 January 2012
 

TRADING UPDATE - 9 JANUARY 2012

 

 

 

Persimmon plc announces the following update ahead of its Final Results for the year ended 31 December 2011, which will be released on Tuesday 28 February 2012.

 

As indicated in our Interim Management Statement on 8th November 2011, our new home legal completions were maintained year on year at 9,360 (2010: 9,384). Total revenues for the period were c. £1.53 billion. Take up of the Government's FirstBuy Scheme has been encouraging and as a result we have legally completed more starter homes in 2011 and the Group's average selling price is therefore c. 2% lower than the prior year at c. £164,000. Legal completions of new homes in the second half of the year were over 4% higher than for the prior year at 4,921.

 

We anticipate that our underlying operating margin for the year will approach 10.0%, with a margin for the second half of over 10.5%. In line with our stated strategy we continue to focus on delivering increasing profitability through a combination of securing improvements in existing planning permissions, good cost control, opening new outlets from recently acquired land and the conversion of land from our significant strategic land bank for future development.

 

As a result of this significant improvement in underlying operating profitability, combined with a reduction in net finance costs, we anticipate an increase of c. 50% in underlying profit before tax. This result will be towards the top end of analysts' expectations.1

 

We have continued to generate good levels of free cashflow and held c. £40 million of cash balances at 31 December 2011 (2010: borrowings of £51.0 million).

 

Our focus on selective replacement of land enabled us to acquire c. 7,000 plots of high quality new land in the second half of 2011. Plots owned and under control in our consented landbank at 31 December 2011 totalled c. 63,500 plots (2010: 58,862 plots).

 

Whilst the general economic backdrop to the UK housing market remains challenging we have experienced encouraging levels of visitors, resilient sales reservations, low cancellation rates and stable prices. As previously reported, we saw a return of the traditionally stronger autumn selling season in 2011. The improvement in the rate of sale when compared to the prior year has continued and as a result we have forward sales of c. £615 million (2010: £565 million) which places us in a strong position moving into the New Year.

 

The availability of mortgage credit remains constrained. We welcome the Government's action in working with both the housebuilding industry and the mortgage lenders to secure the introduction of a 95% loan-to-value mortgage product to support greater participation of buyers in the new homes market. We will continue to work with all stakeholders and hope to see this scheme launched into the spring market in 2012.

 

In anticipation of an active spring 2012 selling season we have opened c. 25 new sites in the last quarter of 2011 and, subject to market conditions, we expect to open a further c. 60 new developments as we progress through the first six months of 2012. This programme of new outlet openings will continue to refresh our site network, which we expect to maintain at c. 390 active sites through the first half of 2012.

 

We will give a further update on our assessment of the housing market over the early weeks of 2012 when we announce our results for the year ended 31 December 2011 on Tuesday 28 February 2012.

 

 

[1] Note: Analysts expectations for underlying profit before tax for the year ended 31 December 2011 range from £130 million to £148 million with a consensus of £139 million. Underlying profit before tax is stated before goodwill charges and exceptional items.

 

Please Note

There will be a call for analysts at 9am GMT today. Please use the dial-in details below:

 

Telephone number: 0800 634 5205 (UK) or +44 (0) 208 817 9301

Conference code: Persimmon

 

An audiocast of the call will be available on www.corporate.persimmonhomes.com from this afternoon.

 

For further information, please contact:

 

Simon Rigby

Kevin Smith

Lindsay Noton

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

Persimmon plc

Tel: +44 (0) 20 7638 9571 on the day

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199 thereafter

Tel: +44 (0) 20 7638 9571

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBFMRTMBBMBTT
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.